Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.
Latest news and releases
-
Herantis Pharma announces publication of preclinical HER-096 data in Cell Chemical Biology journal
Read more » -
Herantis Pharma Plc’s resolutions of the Extraordinary General Meeting
Read more » -
Composition of Herantis Pharma Plc’s Shareholders’ Nomination Committee
Read more » -
Meet Herantis Pharma at BIO-Europe 2023 in Munich, Germany
Read more » -
Notice to Convene Herantis Pharma Plc’s Extraordinary General Meeting of Shareholders
Read more » -
Inside information: Herantis Pharma announces positive topline data from the Phase 1a clinical trial of HER-096, a disease modifying therapeutic developed for Parkinson’s disease
Read more »